原发部位不明腺癌

Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.全文  摘要

Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005. 摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: occult primary (cancer of unknown primary).全文

Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.全文  摘要

Diggs CH. Cancer of unknown primary site. Deciding how far to carry evaluation. Postgrad Med. 1989;86:186-191. 摘要

Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med. 1986;104:547-553. 摘要

Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479-3482. 摘要

Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272-1280. 摘要

1. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776-1785.全文  摘要

2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.全文  摘要

3. Muir C. Cancer of unknown primary site. Cancer. 1995;75:353-356. 摘要

4. Coates M, Armstrong B. Cancer in New South Wales. Incidence and mortality 1994. Sydney: NSW Cancer Council; 1997.

5. Parkin DM, Muir CS. Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ. 1992;120:45-173. 摘要

6. Neumann G. The impact of cancer with unspecified site. Off Gesundheitswes. 1988;50:13-19.

7. Naresh KN. Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site?-a hypothesis. Med Hypotheses. 2002;59:357-360. 摘要

8. Van't Veer LJ, Weigelt B. Road map to metastasis. Nat Med. 2003;9:999-1000. 摘要

9. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537-549. 摘要

10. Hedley DW, Leary JA, Kirsten F. Metastatic adenocarcinoma of unknown primary site: abnormalities of cellular DNA content and survival. Eur J Cancer Clin Oncol. 1985;21:185-189. 摘要

11. Pavlidis N, Briasoulis E, Hainsworth J, et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990-2005. 摘要

12. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 2001;61:7388-7393.全文  摘要

13. Leader M, Patel J, Makin C, et al. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology. 1986;10:1315-1324. 摘要

14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: occult primary (cancer of unknown primary).全文

15. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766-3772.全文  摘要

16. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol. 2010;18:3-8. 摘要

17. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev. 2009;35:221-227. 摘要

18. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43:2026-2036. 摘要

19. Diggs CH. Cancer of unknown primary site. Deciding how far to carry evaluation. Postgrad Med. 1989;86:186-191. 摘要

20. Latief KH, White CS, Protopapas Z, et al. Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? AJR Am J Roentgenol. 1997;168:1339-1344.全文  摘要

21. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol. 2009;19:731-744.全文  摘要

22. Pelosi E, Pennone M, Deandreis D, et al. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imaging. 2006;50:15-22. 摘要

23. Sève P, Billotey C, Broussolle C, et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109:292-299.全文  摘要

24. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med. 2010;134:216-224.全文  摘要

25. Bender RA, Erlander MG. Molecular classification of unknown primary cancer. Semin Oncol. 2009;36:38-43. 摘要

26. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-726. 摘要

27. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233:830-849.全文  摘要

28. Kupesic S, Plavsic BM. Early ovarian cancer: 3-D power Doppler. Abdom Imaging. 2006;31:613-619. 摘要

29. Della-Fiorentina SA, Jaworski RC, Crandon AJ, et al. Primary peritoneal carcinoma: a treatable subset of patients with adenocarcinoma of unknown primary. Aust N Z J Surg. 1996;66:124-125. 摘要

30. Regelink G, Brouwer J, de Bree R, et al. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging. 2002;29:1024-1030. 摘要

31. Wei S, Said-Al-Naief N, Hameed O. Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol. 2009;17:393-402. 摘要

32. Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386-399. 摘要

33. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. 摘要

34. Amela EY, Lauridant-Philippin G, Cousin S, et al. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature. Crit Rev Oncol Hematol. 2012;84:213-223.全文  摘要

35. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med. 1986;104:547-553. 摘要

36. Sporn JR, Greenberg BR. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site. Semin Oncol. 1993;20:261-267. 摘要

37. Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003;21:3479-3482. 摘要

38. Dowell JE, Garrett AM, Shyr Y, et al. A randomized phase II trial in patients with carcinoma of an unknown primary site. Cancer. 2001;91:592-597.全文  摘要

39. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000;11:211-215.全文  摘要

40. Golfinopoulos V, Pentheroudakis G, Salanti G, et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009;35:570-573. 摘要

41. Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol. 2007;25:2867-2872. 摘要

42. Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med. 1988;109:364-371. 摘要

43. Ricci S, Antonuzzo A, Galli L, et al. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Ann Oncol. 2000;11:1127-1130.全文  摘要

44. Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002;20:1651-1656. 摘要

45. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358:1663-1671. [Errata in: N Engl J Med. 2008;359:106; N Engl J Med. 2009;360:1685.]全文  摘要

46. Hainsworth JD, Spigel DR, Farley C, et al. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007;25:1747-1752.全文  摘要

47. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002;38:409-413. 摘要

48. Abbruzzese JL, Abbruzzese MC, Hess KR, et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12:1272-1280. 摘要

49. Hayes DF. Prognostic and predictive factors revisited. Breast. 2005;14:493-499. 摘要

50. Kennedy AW, Markman M, Webster KD, et al. Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum. Gynecol Oncol. 1998;71:288-290. 摘要

51. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer. 2006;42:1031-1039. 摘要